Cargando…

HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing

Trastuzumab-based therapy has been shown to confer overall survival benefit in HER2-positive patients with advanced gastric cancer in a large multicentric trial (ToGA study). Subgroup analysis identified adenocarcinomas of the stomach and gastroesophageal (GE) junction with overexpression of HER2 ac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rüschoff, Josef, Dietel, Manfred, Baretton, Gustavo, Arbogast, Susanne, Walch, Axel, Monges, Geneviéve, Chenard, Marie-Pierre, Penault-Llorca, Frédérique, Nagelmeier, Iris, Schlake, Werner, Höfler, H., Kreipe, H. H.
Formato:	Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2010
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2933810/ https://www.ncbi.nlm.nih.gov/pubmed/20665045 http://dx.doi.org/10.1007/s00428-010-0952-2

Ejemplares similares

Physical basis of the ‘magnification rule’ for standardized Immunohistochemical scoring of HER2 in breast and gastric cancer
por: Scheel, Andreas H., et al.
Publicado: (2018)

Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study
por: van de Vijver, Marc, et al.
Publicado: (2007)

HER2 testing in gastric cancer: results of a German expert meeting
por: Lordick, Florian, et al.
Publicado: (2017)

Comparison of HercepTest™ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status
por: Rüschoff, Josef, et al.
Publicado: (2022)

HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer
por: Styczen, Hanna, et al.
Publicado: (2015)

Comparison of different commercial kits for HER2 testing in breast cancer: looking for the accurate cutoff for amplification
por: Cayre, Anne, et al.
Publicado: (2007)

EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer
por: Varella-Garcia, M, et al.
Publicado: (2009)

Decentral gene expression analysis for ER+/Her2− breast cancer: results of a proficiency testing program for the EndoPredict assay
por: Denkert, Carsten, et al.
Publicado: (2012)

Development of automated brightfield double In Situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence In Situ hybridization (FISH)
por: Nitta, Hiroaki, et al.
Publicado: (2008)

Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice
por: Dupouy, Sandra, et al.
Publicado: (2014)

Morphological and Immunohistochemical Study of Ovarian and Tubal Dysplasia Associated with Tamoxifen
por: Chene, G., et al.
Publicado: (2014)

EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations
por: Thunnissen, Erik, et al.
Publicado: (2012)

Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer
por: Siena, S, et al.
Publicado: (2018)

Evaluation of C-ErbB-2 Overexpression and Her-2/neu Gene Copy Number Heterogeneity in Barrett’s Adenocarcinoma
por: Walch, Axel, et al.
Publicado: (2000)

HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients
por: Tuefferd, Marianne, et al.
Publicado: (2007)

Testung auf Mismatch-Reparatur-Defizienz und Mikrosatelliteninstabilität: Eine fokussierte Aktualisierung
por: Rüschoff, Josef, et al.
Publicado: (2023)

aHIF but not HIF-1α transcript is a poor prognostic marker in human breast cancer
por: Cayre, Anne, et al.
Publicado: (2003)

Testing algorithm for identification of patients with TRK fusion cancer
por: Penault-Llorca, Frédérique, et al.
Publicado: (2019)

Microdissection and Molecular Analysis of Single Cells or Small Cell Clusters in Pathology and Diagnosis – Significance and Challenges
por: Heinmöller, E., et al.
Publicado: (2002)

p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results.
por: Jacquemier, J., et al.
Publicado: (1994)

From Targeting Somatic Mutations to Finding Inherited Cancer Predispositions: The Other Side of the Coin
por: Pujol, Pascal, et al.
Publicado: (2019)

Neue Therapiemöglichkeiten beim metastasierten HER2-low-Mammakarzinom: Konsequenzen für die histopathologische Diagnostik
por: Denkert, Carsten, et al.
Publicado: (2022)

La recherche de la surexpression de la protéine et l'amplification du gène HER2 dans le cancer de l'estomac par immunohistochimie et Hybridation in Situ: expérience du CHU HASSAN II de Fès
por: El Fatemi, Hinde, et al.
Publicado: (2012)

P-gp expression in brown trout erythrocytes: evidence of a detoxification mechanism in fish erythrocytes
por: Valton, Emeline, et al.
Publicado: (2013)

Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer
por: Guiu, S, et al.
Publicado: (2010)

Circulating proteins as predictive and prognostic biomarkers in breast cancer
por: Veyssière, Hugo, et al.
Publicado: (2022)

Immunohistochemical Assessment of HER3 Expression in Odontogenic Cysts
por: Honarmand, Marieh, et al.
Publicado: (2015)

Testing for ROS1 in non-small cell lung cancer: a review with recommendations
por: Bubendorf, Lukas, et al.
Publicado: (2016)

MALDI imaging mass spectrometry for direct tissue analysis: a new frontier for molecular histology
por: Walch, Axel, et al.
Publicado: (2008)

Quality assessment of HER2 testing by monitoring of positivity rates
por: Choritz, Harald, et al.
Publicado: (2011)

Mini-P-gp and P-gp Co-Expression in Brown Trout Erythrocytes: A Prospective Blood Biomarker of Aquatic Pollution
por: Valton, Emeline, et al.
Publicado: (2015)

Breaking down the Contradictory Roles of Histone Deacetylase SIRT1 in Human Breast Cancer
por: Rifaï, Khaldoun, et al.
Publicado: (2018)

Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells
por: El Guerrab, Abderrahim, et al.
Publicado: (2020)

Immunohistochemical expression of vegf and her-2 proteins in osteosarcoma biopsies
por: Becker, Ricardo Gehrke, et al.
Publicado: (2013)

Immunohistochemical evaluation of HER2 expression in canine thyroid carcinoma
por: Yoshimoto, Sho, et al.
Publicado: (2019)

An immunohistochemical study of HER2 expression in primary brain tumors
por: Ramezani, Mazaher, et al.
Publicado: (2020)

HER2 Oncogene Amplification and Immunohistochemical Profiling in Gastric Adenocarcinoma
por: Raj, Nisha, et al.
Publicado: (2018)

HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer
por: Schulz, R, et al.
Publicado: (2014)

Interest and Limits of [(18)F]ML-10 PET Imaging for Early Detection of Response to Conventional Chemotherapy
por: Jouberton, Elodie, et al.
Publicado: (2021)

SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases
por: Jacquemier, Jocelyne, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_dgfkdc5opd49ndkfdjnfim0tsk